Skip to main content

Table 1 Demographic data for ten consecutive living-related donor renal transplant patients (P1 to P10) studied

From: The feasibility and applications of non-invasive cardiac output monitoring, thromboelastography and transit-time flow measurement in living-related renal transplantation surgery: results of a prospective pilot observational study

Patient Age (yrs) Height (cm) Weight (kg) Body surface area (m2) Body mass index (kg/m2) Ethnicity Dialysis status Previous transplant CMV (donor/recipient) ESRF cause
P1 30 161 64 1.67 24.7 White European HDb (fistula) N -/+ Henoch-Schonlein Purpura
P2 45 177 101 2.18 32.2 White European Pre-dialysis N -/- ?Hypertensive nephropathy
P3 41 179 77 1.96 24.0 White European Pre-dialysis N -/- FSGSc
P4 24 157 50.4 1.49 20.4 White European Pre-dialysis N +/+ ?Hypertensive nephropathy
P5a 41 157 66.4 1.67 26.9 South Asian HDb (vascath) N -/+ DM nephropathy
P6 44 185 83 2.07 24.3 White European HDb (fistula) Y -/- Hypertensive (prev. traumatic nephrectomy)
Cadaveric ×2 (1993/2010)
dAIT
P7 58 168 58.8 1.67 20.8 South Asian HDb (fistula) N +/+ Membranous nephropathy
P8 23 161 49.6 1.5 19.1 White European CAPD N -/- Chronic pyelonephritis
P9 48 169 77.4 1.88 27.1 White European HDb (fistula) N -/- IgA nephropathy
P10 37 189 90.6 2.18 25.4 White European Pre-dialysis N -/- IgA nephropathy
  1. aP5 (highlighted) demonstrated DGF at 7-days post-operatively. bHD, haemodialysis; cFSGS, focal segmental glomerulosclerosis; dAIT, antibody incompatible transplantation.
  2. Of the individuals studied, one incidence of DGF was noted (10%; P5). One intra-operative complication (10%; P3; thrombus at the arterial anastomosis, requiring thrombectomy and revision of the anastomosis) identified. One patient was postoperatively commenced on anti-rejection therapy (anti-thymoglobulin antibody) (10%; P7; within the period of follow-up, but did not demonstrate DGF).